IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v40y2022i3d10.1007_s40273-021-01106-6.html
   My bibliography  Save this article

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Author

Listed:
  • Timothy Spelman

    (Monash University)

  • William L. Herring

    (RTI Health Solutions)

  • Yuanhui Zhang

    (RTI Health Solutions)

  • Michael Tempest

    (Biogen)

  • Isobel Pearson

    (RTI Health Solutions)

  • Ulrich Freudensprung

    (Medical, Biogen)

  • Carlos Acosta

    (Biogen International GmbH)

  • Thibaut Dort

    (Biogen International GmbH)

  • Robert Hyde

    (Medical, Biogen)

  • Eva Havrdova

    (General University Hospital and Charles University)

  • Dana Horakova

    (General University Hospital and Charles University)

  • Maria Trojano

    (University of Bari)

  • Giovanna Luca

    (University “G. d’Annunzio”)

  • Alessandra Lugaresi

    (IRCCS Istituto delle Scienze Neurologiche di Bologna
    Università di Bologna)

  • Guillermo Izquierdo

    (Hospital Universitario Virgen Macarena)

  • Pierre Grammond

    (Centre de Réadaptation Déficience Physique Chaudière-Appalache)

  • Pierre Duquette

    (Hôpital Notre Dame)

  • Raed Alroughani

    (Amiri Hospital)

  • Eugenio Pucci

    (ASUR Marche-AV3)

  • Franco Granella

    (University of Parma)

  • Jeannette Lechner-Scott

    (John Hunter Hospital)

  • Patrizia Sola

    (Azienda Ospedaliero Universitaria Policlinico/OCB, Neurology Unit)

  • Diana Ferraro

    (University of Modena and Reggio Emilia)

  • Francois Grand’Maison

    (Neuro Rive-Sud, Hôpital Charles LeMoyne)

  • Murat Terzi

    (Mayis University)

  • Csilla Rozsa

    (Jahn Ferenc Teaching Hospital)

  • Cavit Boz

    (Karadeniz Technical University)

  • Raymond Hupperts

    (Zuyderland Medical Center)

  • Vincent Pesch

    (Cliniques Universitaires Saint-Luc)

  • Celia Oreja-Guevara

    (Hospital ClínicoSan Carlos)

  • Anneke Walt

    (Monash University)

  • Vilija G. Jokubaitis

    (Monash University)

  • Tomas Kalincik

    (University of Melbourne
    Royal Melbourne Hospital)

  • Helmut Butzkueven

    (Monash University)

Abstract

Background Patients with highly active relapsing-remitting multiple sclerosis inadequately responding to first-line therapies (interferon-based therapies, glatiramer acetate, dimethyl fumarate, and teriflunomide, known collectively as “BRACETD”) often switch to natalizumab or fingolimod. Objective The aim was to estimate the comparative effectiveness of switching to natalizumab or fingolimod or within BRACETD using real-world data and to evaluate the cost-effectiveness of switching to natalizumab versus fingolimod using a United Kingdom (UK) third-party payer perspective. Methods Real-world data were obtained from MSBase for patients relapsing on BRACETD in the year before switching to natalizumab or fingolimod or within BRACETD. Three-way-multinomial-propensity-score–matched cohorts were identified, and comparisons between treatment groups were conducted for annualised relapse rate (ARR) and 6-month–confirmed disability worsening (CDW6M) and improvement (CDI6M). Results were applied in a cost-effectiveness model over a lifetime horizon using a published Markov structure with health states based on the Expanded Disability Status Scale. Other model parameters were obtained from the UK MS Survey 2015, published literature, and publicly available UK sources. Results The MSBase analysis found a significant reduction in ARR (rate ratio [RR] = 0.64; 95% confidence interval [CI] 0.57–0.72; p

Suggested Citation

  • Timothy Spelman & William L. Herring & Yuanhui Zhang & Michael Tempest & Isobel Pearson & Ulrich Freudensprung & Carlos Acosta & Thibaut Dort & Robert Hyde & Eva Havrdova & Dana Horakova & Maria Troja, 2022. "Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the Unit," PharmacoEconomics, Springer, vol. 40(3), pages 323-339, March.
    • Handle: RePEc:spr:pharme:v:40:y:2022:i:3:d:10.1007_s40273-021-01106-6
    DOI: 10.1007/s40273-021-01106-6
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-021-01106-6
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-021-01106-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Bruce A. Craig & Peter P. Sendi, 2002. "Estimation of the transition matrix of a discrete‐time Markov chain," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 33-42, January.
    2. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629, Decembrie.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Risha Gidwani & Louise B. Russell, 2020. "Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers," PharmacoEconomics, Springer, vol. 38(11), pages 1153-1164, November.
    2. Beate Jahn & Christina Kurzthaler & Jagpreet Chhatwal & Elamin H. Elbasha & Annette Conrads-Frank & Ursula Rochau & Gaby Sroczynski & Christoph Urach & Marvin Bundo & Niki Popper & Uwe Siebert, 2019. "Alternative Conversion Methods for Transition Probabilities in State-Transition Models: Validity and Impact on Comparative Effectiveness and Cost-Effectiveness," Medical Decision Making, , vol. 39(5), pages 509-522, July.
    3. Jagpreet Chhatwal & Suren Jayasuriya & Elamin H. Elbasha, 2016. "Changing Cycle Lengths in State-Transition Models," Medical Decision Making, , vol. 36(8), pages 952-964, November.
    4. Chiranjeev Sanyal & Don Husereau, 2020. "Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 375-392, June.
    5. Arantzazu Arrospide & Oliver Ibarrondo & Iván Castilla & Igor Larrañaga & Javier Mar, 2022. "Development and Validation of a Discrete Event Simulation Model to Evaluate the Cardiovascular Impact of Population Policies for Obesity," Medical Decision Making, , vol. 42(2), pages 241-254, February.
    6. Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi, 2021. "Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 711-721, July.
    7. Kaitlyn Hastings & Clara Marquina & Jedidiah Morton & Dina Abushanab & Danielle Berkovic & Stella Talic & Ella Zomer & Danny Liew & Zanfina Ademi, 2022. "Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia," PharmacoEconomics, Springer, vol. 40(4), pages 449-460, April.
    8. Andrea Marcellusi & Raffaella Viti & Loreta A. Kondili & Stefano Rosato & Stefano Vella & Francesco Saverio Mennini, 2019. "Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data," PharmacoEconomics, Springer, vol. 37(2), pages 255-266, February.
    9. Round, Jeff, 2012. "Is a QALY still a QALY at the end of life?," Journal of Health Economics, Elsevier, vol. 31(3), pages 521-527.
    10. Xinyue Dong & Xiaoning He & Jing Wu, 2022. "Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting," PharmacoEconomics, Springer, vol. 40(12), pages 1187-1205, December.
    11. Joseph F. Levy & Marjorie A. Rosenberg, 2019. "A Latent Class Approach to Modeling Trajectories of Health Care Cost in Pediatric Cystic Fibrosis," Medical Decision Making, , vol. 39(5), pages 593-604, July.
    12. Jisoo A Kwon & Georgina M Chambers & Fabio Luciani & Lei Zhang & Shamin Kinathil & Dennis Kim & Hla-Hla Thein & Willings Botha & Sandra Thompson & Andrew Lloyd & Lorraine Yap & Richard T Gray & Tony B, 2021. "Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis," PLOS ONE, Public Library of Science, vol. 16(2), pages 1-13, February.
    13. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    14. Jorge Luis García & James J. Heckman, 2021. "Early childhood education and life‐cycle health," Health Economics, John Wiley & Sons, Ltd., vol. 30(S1), pages 119-141, November.
    15. Stephen Morris & Kurinchi S Gurusamy & Jessica Sheringham & Brian R Davidson, 2015. "Cost-Effectiveness Analysis of Endoscopic Ultrasound versus Magnetic Resonance Cholangiopancreatography in Patients with Suspected Common Bile Duct Stones," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-12, March.
    16. Tushar Srivastava & Nicholas R. Latimer & Paul Tappenden, 2021. "Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals," PharmacoEconomics, Springer, vol. 39(8), pages 869-878, August.
    17. Eleanor Heather & Katherine Payne & Mark Harrison & Deborah Symmons, 2014. "Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models," PharmacoEconomics, Springer, vol. 32(2), pages 109-134, February.
    18. Manuel Gomes & Robert Aldridge & Peter Wylie & James Bell & Owen Epstein, 2013. "Cost-Effectiveness Analysis of 3-D Computerized Tomography Colonography Versus Optical Colonoscopy for Imaging Symptomatic Gastroenterology Patients," Applied Health Economics and Health Policy, Springer, vol. 11(2), pages 107-117, April.
    19. Isaac Corro Ramos & Maureen P. M. H. Rutten-van Mölken & Maiwenn J. Al, 2013. "The Role of Value-of-Information Analysis in a Health Care Research Priority Setting," Medical Decision Making, , vol. 33(4), pages 472-489, May.
    20. Chantal Guilhaume & Delphine Saragoussi & John Cochran & Clément François & Mondher Toumi, 2010. "Modeling stroke management: a qualitative review of cost-effectiveness analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(4), pages 419-426, August.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:40:y:2022:i:3:d:10.1007_s40273-021-01106-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.